Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens
| Autor: | Kitty M. C. Kwappenberg, R.M.P. Brandt, C. J. M. Melief, Julian Hickling, S.H. van der Burg, T. O'Neill, R. Offringa |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Papillomavirus E7 Proteins
Recombinant Fusion Proteins viruses medicine.medical_treatment Drug Evaluation Preclinical Heterologous Biology Cervical intraepithelial neoplasia Cancer Vaccines Cell Line Mice chemistry.chemical_compound Capsid Vaccines Acellular Immune system Antigens Neoplasm Immunity medicine Animals Antigens Viral Papillomaviridae neoplasms Cell Line Transformed General Veterinary General Immunology and Microbiology Public Health Environmental and Occupational Health virus diseases Oncogene Proteins Viral Immunotherapy Uterine Cervical Dysplasia medicine.disease Virology Fusion protein female genital diseases and pregnancy complications Mice Inbred C57BL CTL Infectious Diseases chemistry Molecular Medicine Capsid Proteins Vaccinia |
| Zdroj: | Vaccine, 19, 3652-3660. Elsevier |
| ISSN: | 0264-410X |
| Popis: | Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model. These immune responses effectively prevented outgrowth of HPV16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease setting. CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine. These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect